Audrey Plaut

Market Access Strategy @JNJInnovMed. All views my own.

[Audrey Plaut @AudreyPlaut]

What happens when you lack sufficient savings to cover your private health insurance OOP costs?

For many people in the U.S., this is reality.

The chart says it all ⬇️

@KFF https://t.co/v5Q59Sse6q

[Audrey Plaut @AudreyPlaut]

Newer neurologic meds with similar benefits to older drugs are used by fewer than 20% of patients due to high costs + unpredictable OOP according to @GreenJournal

Huge spread between most expensive drugs - from $91/mo to $713/mo. https://t.co/msXgstwrqx

[Audrey Plaut @AudreyPlaut]

Disappointing, not surprising: insurer promises to reform prior authorization in 2018 = #fail

Majority of physicians (~85%) reported that PAs have actually INCREASED in past 5 years

Changes unlikely w/o accountability

@AmerMedicalAssn https://t.co/he7QfOLN5G

[Audrey Plaut @AudreyPlaut]

Rare diseases are undercounted according to new report from @RARE_X_

The research counts up to 10,867 (!) rare diseases

Better understanding & counting means more investment, research, and treatments for patients

Full report: https://t.co/NCv86wQ0Hi

[Audrey Plaut @AudreyPlaut]

This year @Accenture was recognized by @IDC as a leader in #lifesciences sales and marketing #IT outsourcing services

Our clients understand the end-to-end value of our business: from industry expertise to technical capabilities https://t.co/7dbzOKFt9S

[Audrey Plaut @AudreyPlaut]

Interesting perception vs. reality for prescription drugs: the public says costs are unreasonable, while the majority people taking prescriptions find them affordable

#foodforthought

via @KFF https://t.co/1BmwpT6ZhT

[Audrey Plaut @AudreyPlaut]

“Value-based price for value-based access" model from @Novartis:
+makes patient access easier
+lowers cost-sharing
+reduces admin burden

More innovative concepts needed to decrease reliance on high list price/high rebate model

@Accenture @PharmaCommerce https://t.co/TEyG6oi8pe

[Audrey Plaut @AudreyPlaut]

Changing policy tides: in the past year 38 (!) states expanded coverage for #telehealth.

These policies increased access to care & might be a sign #telehealth is here to stay.

Will the last 12 states follow suit?

From @avalerehealth '22 outlook. https://t.co/TDUPBYcDgp

[Audrey Plaut @AudreyPlaut]

What do patients think of #biosimilars?

Turns out:
-most patients have limited knowledge
-switching does not reduce satisfaction
-AND the # of switches does not reduce satisfaction

Interesting study from @ACRheum https://t.co/eqTHqMj6o0

[Audrey Plaut @AudreyPlaut]

Lots of cell & gene therapies on the horizon, but @IQVIA_global has a mixed outlook for commercial success. https://t.co/CtasGxbUfJ

Therapies have high costs, small patient pops, and are expected to be <10% of spending on new drugs in the next 5 yrs.

Expect payer resistance...

[Audrey Plaut @AudreyPlaut]

From @IQVIA_global: specialty meds are expected to encompass ~45% of global drug spending in the next 5 yrs. https://t.co/CtasGxbUfJ

Notable that the growth rate is higher in developed countries with better access.

Context: these medications treat around 2-3% of patients.

[Audrey Plaut @AudreyPlaut]

Another example of #digitalhealth improving access to treatment: @GetWithinHealth

Eating disorder patients have direct communication with their care team anywhere, anytime, and from their homes. https://t.co/PorujpXDpW

[Audrey Plaut @AudreyPlaut]

Why do some patients give up on cancer treatment?

Study from @IQVIA_US paints an ugly picture: some #breastcancer patients did not initiate treatment b/c of a formulary exclusion.

Instead they opted for symptom management, chemo or other products. Sad. https://t.co/PGPxtrlsQQ

[Audrey Plaut @AudreyPlaut]

More pressure on state governments to ban copay #accumulator programs.

Latest: Massachussets.

Last week advocates from patient orgs across the state testified in front of the Joint Committee on Financial Services to pass legislation https://t.co/ScgUyg589N

[Audrey Plaut @AudreyPlaut]

Hospitals receive more $$$ than physician offices for infused #cancer drugs.

Payers then try to shift care to non-hospital settings to reduce exposure to higher prices...

Patient impact: potentially higher cost-sharing burden. @Health_Affairs https://t.co/AjyAS8AlAv

[Audrey Plaut @AudreyPlaut]

People at risk of HIV continue to face unnecessary coverage barriers for PrEP.

The ACA requires plans to cover PrEP with no cost-sharing, but several insurers are noncompliant.

Worthwhile opinion from @statnews brings this issue to light @HIVHep https://t.co/pCDVHBeitw

[Audrey Plaut @AudreyPlaut]

Patient experiences / experience data have become an important part of drug R&D and regulatory reviews.

Latest example: @US_FDA PDUFA VII commitment letter calls for a "patient focused drug development meeting" to understand perspectives on #cellandgene https://t.co/nO8gUwFzDE

[Audrey Plaut @AudreyPlaut]

According to new @Accenture survey, younger people experience more access barriers than older people.

Over half surveyed aged 57-74 claimed to have never experienced and issue affording medical care.

Hypothesis: higher millennial enrollment in HDHPs? https://t.co/wUgLvHcMQi

[Audrey Plaut @AudreyPlaut]

@bgurley @CastlightHealth @healthcaredive Not saying price should be hidden! My point was that transparency is needed for additional metrics that would be helpful for patients in selecting a provider - network, ratings, safety, quality, etc. Patients often (wrongfully) assume higher price = better care

[Audrey Plaut @AudreyPlaut]

It's no surprise that the No Surprises Act will be hard to implement.

Good summary of some reasons why in @healthcaredive.

One point I liked: the Act focuses too much on cost when cost is just one of many factors patients consider

https://t.co/Q5munQYkef @CastlightHealth